Grey Wolf Therapeutics
Greywolf Therapeutics
United Kingdom · Founded 2017 · $115.6M raised
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- greywolftherapeutics.com
- Total Funding
- $115.6M
- Last Round
- $50.0M Series BMay 2024
- Rounds
- 4
About
Clinical-stage biotech developing antigen modulation therapies targeting cancer, autoimmune conditions, and infectious diseases.
Summary
Grey Wolf Therapeutics is a Biotech company based in United Kingdom, founded in 2017. It has raised $115.6M in total across 4 rounds, most recently a $50.0M Series B round in May 2024. Investors include ICG Life Sciences, Pfizer Ventures and Earlybird Venture Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...